Shriniwas Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 20.00 Cr
as on 17-11-2024
- Paid Up Capital ₹ 13.77 Cr
as on 17-11-2024
- Company Age 4 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 44.00 Cr
as on 17-11-2024
- Revenue %
(FY 2023)
- Ebitda
- Net Worth 14.64%
(FY 2023)
- Total Assets 78.46%
(FY 2023)
About Shriniwas Pharmachem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 20.00 Cr and a paid-up capital of Rs 13.77 Cr.
The company currently has active open charges totaling ₹44.00 Cr.
The Key Managerial Personnel (KMP) at Shriniwas Pharmachem Private Limited India is Payal Jain as COMPANY SECRETARY. Vishnu Jajoo and Arpit Bangur serve as directors at the Company.
- CIN/LLPIN
U24234MP2020PTC051488
- Company No.
051488
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jun 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Ujjain, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Shriniwas Pharmachem?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Payal Jain | Company Secretary | 02-Apr-2024 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vishnu Jajoo  | Director | 13-Jun-2020 | Current |
| Arpit Bangur | Director | 13-Jun-2020 | Current |
Financial Performance of Shriniwas Pharmachem.
Shriniwas Pharmachem Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 14.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Shriniwas Pharmachem?
In 2023, Shriniwas Pharmachem had a promoter holding of 36.07% and a public holding of 63.93%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shriji Polymers Medical Devices Private LimitedActive 2 years 2 monthsVishnu Jajoo is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 07 Nov 2022 | ₹44.00 Cr | Open |
How Many Employees Work at Shriniwas Pharmachem?
Shriniwas Pharmachem has a workforce of 41 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shriniwas Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shriniwas Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
